Member Info for B2HS2L

HC, - I don't think JW is interested in anything but 100%, if he's interested at all.

He is only interested in fire sales, and it's rich pickings for NCYT in June if the DHSC claim is refuted.

Seems like nothing was off the table.

He chose the questions Katy asked, and prepared his answers accordingly.

I'm sure that's why he had so much to say answering some.

SG is JW's man.

I believe he will be overseeing LR's plans, JW will have final say, - no change there.

IMO

JW orchestrating management moves, - not before time, (SG in place already).

JM not the chosen one. - No surprise there.

The guy with the financial power, who will be babysitting Lyn's financial decisions for JW, has settled in.

Everyone owes their opportunity to JW.

Agree DHSC dispute is as good as won (in the eyes of JW).

Still think we are likely to go to court.

Does Avacta have a longer term though?

We have to announce some LD's soon else the sp will be too low to ignore for some BP's even short term.

Sure they'll want to see Q2W complete successfully, but it's open season after that,

and we don't want the auction to the highest bidder to start too low.

As has been said before, AVA6K is not just a drug but a platform which could launch (or relaunch) many Therapeutics.

I believe that will be some auction, - akin to dozens of Piranha selecting a target.

IMO the sp has not responded to last nights news because too many new shares

issued in March have not found sticky hands yet.

Many here think tonight's presentation will cause downward pressure on the sp.

I suspect that is because it is being presented by the CEO.

We'll see.

Should have waited for the AS presentation tonight before publishing.

CTSFO - You posted:

"This is incredible news from the Orphan Drug Designation for AVA6000 and STS. Will they be able to hybrid (my choice of phrase, sorry) a P2+3 trial to get AVA6000 to market quickly?"

If I were AS I would plan to have some cancer patients on the trial who were taking strait Dox only.

Another group of patients would be taking AVA6000, dosed at the (as yet not agreed) RP2D dose, and taking medication

as per the outcome of the Q2W (2 weekly) regime.

The result would surely be a phase 2 trial that would be halted 'for benefit', after which Approval could be expected to be conferred to AVA6K.

That might be one of the quickest ways to Approval.

"The proof-of-concept data presented today with AVA6000 suggest that the peptide drug conjugate drug class has several key advantages, particularly the tumor-specificity of the release of doxorubicin through targeting FAP and simplicity of the manufacturing process which results in SIGNIFICANT SAVINGS IN THE COST OF GOODS"

With the amount of cash spent on ADC's in the last year or two, there will be some very uncomfortable BP head honcho's reading the AVACTA website new projects tonight.

For the record:

pre|CISION™ drug conjugate (PDC)

pre|CISION+ Immuno-peptide drug conjugate

pre|CISION™ ADC

Very much anticipating an update for 59 yo Mr 65% tumour reduction, who started as a patient in Cohort three.

We heard a lot about his situation last December, and there's no reason why we should not get an update next week.

Increased speed of trial can also be attributed to

"Patients can be dosed in parallel in the two-weekly dose escalation study"

GDR Market capitalisation: £10.56 million.

Would JW want to go for 25% when he can have 100%?

I'm not saying he's interested, I just think he might see value in a T/O.

Particularly at this time, as he knows what the situation is re DHSC caving in, or meeting their destiny in court 2 months hence.

Not phase 2data , - Q2W data

WAG -

RNS 28 March

"The webinar will cover the Company's updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company's pre|CISION? peptide drug conjugates that targets chemotherapy to the tumor, which are to be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The updated clinical data will be presented in the Phase 1 Clinical Trials 2 Poster Session on 9 April 2024."

I'm expecting the update to provide the above and much of the data they have withheld, to make the impact they seek at AACR.

To not release this data, will risk it's impact being overtaken and reduced by newer phase 2 data that will be collected and released later this year.

I don't consider I am either Energy, but surely AI has a place in all BP's R&D facilities, and I want to know we are also using it, and what for.

Energy, I asked AS if he would consider making a video on R&D's use of AI in developing products.

He said he and his team are considering it.

(Doesn't sound positive to me, but this might mean AI is in use.)

I hear what you say TVC.

If FDA confer Advanced Approval at end of phase 1 or 2, then that PoV will evaporate quickly.

Anothe part of the problem is Avacta have the rights to Affimer and preCISION Tech, and that leaves other BP paying license fee's, and not being able to use their own facilities and staff to develop new products.

BP has been buying ADC technologies in the past few years, and they are not willing to change their mind about its utility just because of a pretender at stage 1 of it's flagship product.

Yet.

IMO the above situation makes the case that Avacta will be bought out (possibly when FDA approval is imminent or actual).

BP want Avacta to take all the risk with AVA 6000 / 3996 etc, until the FDA have approved a product.

Meanwhile they plough on with their expensive ADC projects.

Two posts in a previous thread 'Avacta Tweet' dovetail well with the info in this one,

from Bella 6532 and jive_turkey, (thank you both for your research).

27 Mar 2024 19:27

27 Mar 2024 19:45

MMAE's or no, Avacta has product(s) to capture significant market share dependent on AVA 6K approval.

Any effort to shut down the narrative here should be adequately compensated by info from these posts.

FWIW RNS 24.01.2021

"The Group is on schedule to select the next clinical development candidate by the end of 2021 from the pre|CISION prodrug pipeline. Lead programmes include AVA3996 a FAPα activated proteasome inhibitor, AVA7500 a FAPα activated platin, and AVA7000 a FAPα activated taxane. These are being developed in close collaboration with Professor William Bachovchin at Tuft's University School of Medicine."

++++

...On the one hand, we know that each chemo, with its own mechanism of action, is better at attacking certain tumours (e.g., dox goes after tumours that are reproducing). So in principle, it could make sense to have multiple Precision drugs.

Q Can AVA 7000 / 7500 be got to market with increased speed once AVA6K is approved, else proceed with AVA 3996.

Ice - I agree with your investment case statements.

IMO the problem is not IF but WHEN the FDA Approval is going to be issued, and the amount of dilution to be incurred by the loan before said Approval arrives.

There is Q2W to complete successfully (at least) to deliver compelling data.

A decreased amount of dilution can be expected after Approval as the sp could be expected to increase - but no plan currently exists to repay in part or whole, the outstanding principle.

Selling Dx is not something they are anticipating for a while it seems.

Dx proceeds likely won't pay off the loan.

AS EF SB & SC would need to prioritise loan repayment to reduce / end dilution

That leaves licensing deals as being the most likely form of income.

Lets see how the sp moves after AACR meeting.